Phase II Study of L-Ornithine L-Aspartate and N-Acetylcysteine in HR+/HER2- Advanced Breast Cancer
A Phase II study is evaluating a combination treatment in HR+/HER2- advanced breast cancer patients who have progressed on standard therapies.
Asset / Drug
Drug and asset intelligence for Fulvestrant with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.